Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis
Study Details
Study Description
Brief Summary
The goal of this study is to compare glutamine combined with thalidomide with glutamine alone in preventing radiation-induced oral mucositis. The aim of this study is to answer whether glutamine plus thalidomide could improve the median incidence time of grade 2 oral mucositis. Participants would be randomly divided into the two groups above mentioned.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Explore the therapeutic efficacy of Glutamine combined with Thalidomide as compared to Glutamine alone in preventing radiation-induced oral mucositis. The primary research endpoint is the median time to the onset of Grade II oral mucositis, defined as the number of days from the start of radiation therapy to the occurrence of Grade II oral mucositis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: glutamine combined with thalidomide L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening. Thalidomide: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take orally at 100mg, once every evening. |
Drug: glutamine combined with thalidomide
Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
Other Names:
|
| Active Comparator: glutamine alone L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening. |
Drug: glutamine alone
Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Median time for the occurrence of Grade 2 radiation-induced oral mucositis [during radiotherapy up to 4 weeks]
Median time for the occurrence of Grade 2 radiation-induced oral mucositis
Secondary Outcome Measures
- incidence rate of ≥grade 2 oral mucositis [during radiotherapy up to 4 weeks]
incidence rate of ≥grade 2 oral mucositis
- Body mass index [during radiotherapy up to 4 weeks]
<18.5kg/m2 indicates underweight, 18.5kg/m2-23.9kg/m2 indicates normal weight, >23.9kg/m2 indicates obesity.
- QOL [during radiotherapy up to 4 weeks]
Out of a total of 60 points, a score less than 20 indicates extremely poor quality of life; 21-30 points indicates poor quality of life; 31-40 points indicates average quality of life; 41-50 points indicates relatively good quality of life; 51-60 points indicates good quality of life.
- adverse effects [during radiotherapy up to 4 weeks]
adverse effects
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 to 75 years old;
-
Patients with postoperative oral malignant tumors confirmed by pathological histology or cytology and requiring radiotherapy;
-
Patients who have received more than 45Gy of radiation in the oral area;
-
ECOG PS (Eastern Cooperative Oncology Group Performance Status) score of 0-1;
-
Basic hematological indicators are normal: White blood cell count ≥ 4×109/L; Absolute neutrophil count ≥ 1.5×109/L; Platelets ≥ 100×10^9/L; Hemoglobin ≥ 90 g/L;
-
Basic renal function is normal: Serum creatinine ≤ 1.5×ULN (Upper Limit of Normal) or
Creatinine Clearance Rate (CrCl) > 60 mL/min (using the Cockcroft-Gault formula):
For women: CrCl = (140 - age) × weight (kg) × 0.85 / (72 × Scr mg/dl) For men: CrCl = (140 - age) × weight (kg) × 1.00 / (72 × Scr mg/dl)
-
Basic liver function is normal: Serum total bilirubin ≤ 1.5×ULN; AST (Aspartate Aminotransferase) ≤ 2.5×ULN; ALT (Alanine Aminotransferase) ≤ 2.5×ULN.
-
Signed written informed consent.
Exclusion Criteria:
-
Participated in another interventional clinical trial within the last 30 days;
-
Patients with severe underlying oral diseases who cannot tolerate radiation therapy;
-
Patients allergic to glutamine and thalidomide;
-
Patients receiving secondary radiation therapy to the oral area;
-
Pregnant women (confirmed by blood or urine HCG testing) or breastfeeding women, or participants of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female participants) until at least 6 months after the last trial treatment;
-
Patients with underlying peripheral neuropathy;
-
Individuals deemed by the researcher to be inappropriate for participation in this study;
-
Unwilling to participate in this study or unable to sign informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University | Xi'an | Shaanxi | China | 710032 |
Sponsors and Collaborators
- Air Force Military Medical University, China
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AFMMUChina-oral mucocitis